Karin Larsson

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Karin Larsson avslutade sin doktorsexamen inom bioteknologi år 2010. Hon fokuserade på produktionen och karakteriseringen av antikroppar för proteomikforskning som en del av Human Protein Atlas-projektet vid Kungliga Tekniska högskolan. Efter doktorsexamen började hon som postdoktor vid Karolinska Institutet på Institutionen för Mikrobiologi, Tumör- och Cellbiologi 2011. Hon flyttade sedan till Institutionen för Medicin, Solna först som postdoktor och sedan som Forskarassistent 2017, en tjänst finansierad av Barncancerfonden.

Forskningsbeskrivning

Karin Larssons forskning inom onkologi fokuserar på prostaglandiners och inflammationens roll i cancerutveckling och hur prostaglandiner påverkar tumörens mikromiljö. Hon använder cellulära 3D modeller för att förstå dynamiken bakom cancerutveckling och terapisvar. Hennes mål är att hitta nya terapeutiska mål för att övervinna resistens mot behandling och förbättra patientresultat.

Undervisning

Utöver hennes forskningsverksamhet har Karin Larsson genomfört flera kurser om undervisning på högskolenivå och deltar som lärare i kurser på kandidat-, magister- och forskarnivå.

Utvalda publikationer

Article: MOLECULAR ONCOLOGY. 2024;18(2):317-335
High-content screening of drug combinations of an mPGES-1 inhibitor in multicellular tumor spheroids leads to mechanistic insights into neuroblastoma chemoresistance
Zaghmi A; Aybay E; Jiang L; Shang M; Steinmetz-Spah J; Wermeling F; Kogner P; Korotkova M; Ostling P; Jakobsson P-J; Seashore-Ludlow B; Larsson K
Article: THE FASEB JOURNAL. 2020;34(8):11101-11114
Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-stroma drug targeting
Kock A; Bergqvist F; Steinmetz J; Elfman LHM; Korotkova M; Johnsen JI; Jakobsson P-J; Kogner P; Larsson K
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2019;176(24):4625-4638
Biological characterization of new inhibitors of microsomal PGE synthase-1 in preclinical models of inflammation and vascular tone
Larsson K; Steinmetz J; Bergqvist F; Arefin S; Spahiu L; Wannberg J; Pawelzik S-C; Morgenstern R; Stenberg P; Kublickiene K; Korotkova M; Jakobsson P-J
Article: EBIOMEDICINE. 2018;32:84-92
Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth
Kock A; Larsson K; Bergqvist F; Eissler N; Elfman LHM; Raouf J; Korotkova M; Johnsen JI; Jakobsson P-J; Kogner P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2015;112(26):8070-8075
COX/mPGES-1/PGE₂ pathway depicts an inflammatory-dependent high-risk neuroblastoma subset
Larsson K; Kock A; Idborg H; Henriksson MA; Martinsson T; Johnsen JI; Korotkova M; Kogner P; Jakobsson P-J

Artiklar

Article: FRONTIERS IN PHARMACOLOGY. 2023;14:1183720
The multiple functions of miR-574-5p in the neuroblastoma tumor microenvironment
Proestler E; Donzelli J; Nevermann S; Breitwieser K; Koch LF; Best T; Fauth M; Wickstrom M; Harter PN; Kogner P; Lavieu G; Larsson K; Saul MJ
Article: JOURNAL OF LIPID RESEARCH. 2022;63(12):100310
Biosynthesis of prostaglandin 15dPGJ₂ -glutathione and 15dPGJ₂-cysteine conjugates in macrophages and mast cells via MGST3
Steinmetz-Spah J; Liu J; Singh R; Ekoff M; Boddul S; Tang X; Bergqvist F; Idborg H; Heitel P; Ronnberg E; Merk D; Wermeling F; Haeggstrom JZ; Nilsson G; Steinhilber D; Larsson K; Korotkova M; Jakobsson P-J
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2022;179(7):1433-1449
Effects of microsomal prostaglandin E synthase-1 inhibition on resistance artery tone in patients with end stage kidney disease
Steinmetz-Spah J; Arefin S; Larsson K; Jahan J; Mudrovcic N; Wennberg L; Stenvinkel P; Korotkova M; Kublickiene K; Jakobsson P-J
Article: JOURNAL OF EXTRACELLULAR VESICLES. 2021;10(12):e12143
Small extracellular vesicle-derived miR-574-5p regulates PGE2-biosynthesis via TLR7/8 in lung cancer
Donzelli J; Proestler E; Riedel A; Nevermann S; Hertel B; Guenther A; Gattenloehner S; Savai R; Larsson K; Saul MJ
Article: EMBO REPORTS. 2021;22(3):e51329
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25⁺/CD54⁺ NK cells
Chen Z; Yang Y; Neo SY; Shi H; Chen Y; Wagner AK; Larsson K; Tong L; Jakobsson P-J; Alici E; Wu J; Cao Y; Wang K; Liu LL; Mao Y; Sarhan D; Lundqvist A
Article: FRONTIERS IN PHARMACOLOGY. 2019;10:636
Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells
Bergqvist F; Ossipova E; Idborg H; Raouf J; Checa A; Englund K; Englund P; Khoonsari PE; Kultima K; Wheelock CE; Larsson K; Korotkova M; Jakobsson P-J
Article: NATURE COMMUNICATIONS. 2018;9(1):1107
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Fernandez AP; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Farnegardh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Hakansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Lain S
Article: CLINICAL SCIENCE. 2016;130(24):2295-2303
Deletion of mPGES-1 affects platelet functions in mice
Raouf J; Mobarrez F; Larsson K; Jakobsson P-J; Korotkova M
Article: PROSTAGLANDINS AND OTHER LIPID MEDIATORS. 2015;120:161-165
Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment
Larsson K; Jakobsson P-J
Article: PLOS ONE. 2014;9(5):e97285
Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors
Muller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2013;110(25):10258-10263
MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells
Zirath H; Frenzel A; Oliynyk G; Segerstrom L; Westermark UK; Larsson K; Persson MM; Hultenby K; Lehtio J; Einvik C; Pahlman S; Kogner P; Jakobsson P-J; Henriksson MA
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2011;370(1-2):14-23
Novel antigen design for the generation of antibodies to G-protein-coupled receptors
Larsson K; Hofstrom C; Lindskog C; Hansson M; Angelidou P; Hokfelt T; Uhlen M; Wernerus H; Graslund T; Hober S
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2009;342(1-2):20-32
Characterization of PrEST-based antibodies towards human Cytokeratin-17
Larsson K; Eriksson C; Schwenk JM; Berglund L; Wester K; Uhlen M; Hober S; Wernerus H
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2006;315(1-2):110-120
Multiplexed PrEST immunization for high-throughput affinity proteomics
Larsson K; Wester K; Nilsson P; Uhlen M; Hober S; Wernerus H
Article: MOLECULAR & CELLULAR PROTEOMICS. 2005;4(12):1920-1932
A human protein atlas for normal and cancer tissues based on antibody proteomics
Uhlén M; Björling E; Agaton C; Szigyarto CA; Amini B; Andersen E; Andersson AC; Angelidou P; Asplund A; Asplund C; Berglund L; Bergström K; Brumer H; Cerjan D; Ekström M; Elobeid A; Eriksson C; Fagerberg L; Falk R; Fall J; Forsberg M; Björklund MG; Gumbel K; Halimi A; Hallin I; Hamsten C; Hansson M; Hedhammar M; Hercules G; Kampf C; Larsson K; Linskog M; Lodewyckx W; Lund J; Lundeberg J; Magnusson K; Malm E; Nilsson P; Ödling J; Oksvold P; Olsson I; Öster E; Ottosson J; Paavilainen L; Persson A; Rimini R; Rockberg J; Runeson M; Sivertsson Å; Sköllermo A; Steen J; Stenvall M; Sterky F; Strömberg S; Sundberg M; Tegel H; Tourle S; Wahlund E; Waldén A; Wan JH; Wernérus H; Westberg J; Wester K; Wrethagen U; Xu LL; Hober S; Pontén F
Article: PROTEOMICS. 2005;5(17):4327-4337
Towards a human proteome atlas:: High-throughput generation of mono-specific antibodies for tissue profiling
Nilsson P; Paavilainen L; Larsson K; Ödling J; Sundberg M; Andersson AC; Kampf C; Persson A; Szigyarto CAK; Ottosson J; Björling E; Hober S; Wernérus H; Wester K; Pontén F; Uhlen M

Alla övriga publikationer

Corrigendum: NATURE COMMUNICATIONS. 2023;14(1):5019
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (vol 14, 5019, 2023)
Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Fernandez AP; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Faernegardh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Hakansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Lain S
Published conference paper: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 2019;1161:89-100
Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma
Larsson K; Kock A; Kogner P; Jakobsson P-J
Corrigendum: NATURE COMMUNICATIONS. 2018;9(1):2071
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Fernandez AP; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Farnegardh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Hakansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Lain S

Om mig

Forskningsbeskrivning

Undervisning

Utvalda publikationer

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI